Drugs / ADR-001
ADR-001
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials · 1 met primary | ||||||
| Phase 1 | NCT04522986 | Aug 2020 → Feb 2021 | COVID-19 | Rohto Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04342325 | Jun 2020 → Nov 2022 | IgA glomerulonephritis | Nagoya University | Completed | Met primary |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03254758 | Jul 2017 → Apr 2023 | cirrhosis of liver | Rohto Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04888949 | Jun 2021 → May 2023 | COVID-19 | Rohto Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ADR-001 | “This is a first-in-human Phase1/2 study of ADR-001, adipose-derived mesenchymal stem cells (AD-MSCs).” NCT03254758 ↗3“An Exploratory Study of ADR-001 in Patients with Severe Pneumonia Caused by SARS-CoV-2 Infection” NCT04522986 ↗ “A Study of ADR-001 in Patients With Severe Pneumonia Caused by SARS-CoV-2 Infection (COVID-19)” NCT04888949 ↗ |
| Known as | AD-MSCs | “Adipose-derived mesenchymal stem cells (AD-MSCs) are administered once a week, total four times intravenously.” NCT04888949 ↗ |
| Known as | Adipose-derived mesenchymal stem cells | “Adipose-derived mesenchymal stem cells (AD-MSCs) are administered once a week, total four times intravenously.” NCT04888949 ↗ |
| Modality | Cell therapy | “adipose-derived mesenchymal stem cells (AD-MSCs)” NCT03254758 ↗ |
| Route | Intravenous | “via intravenous infusion” NCT03254758 ↗ |